306 related articles for article (PubMed ID: 33382205)
21. Predictors of response to anamorelin in gastrointestinal cancer patients with cachexia: a retrospective study.
Iwai N; Sakai H; Oka K; Sakagami J; Okuda T; Hattori C; Taniguchi M; Hara T; Tsuji T; Komaki T; Kagawa K; Doi T; Ishikawa T; Yasuda H; Itoh Y
Support Care Cancer; 2023 Jan; 31(2):115. PubMed ID: 36640181
[TBL] [Abstract][Full Text] [Related]
22. Anamorelin hydrochloride in the treatment of cancer anorexia-cachexia syndrome: design, development, and potential place in therapy.
Graf SA; Garcia JM
Drug Des Devel Ther; 2017; 11():2325-2331. PubMed ID: 28848326
[TBL] [Abstract][Full Text] [Related]
23. Randomised placebo-controlled cross-over study examining the role of anamorelin in mesothelioma (The ANTHEM study): rationale and protocol.
Hoon SN; Fyfe K; Peddle-McIntyre CJ; Bowyer S; Hawkins F; Jeffery E; Chih HJ; Creaney J; Nowak A; Brims F
BMJ Open Respir Res; 2020 Mar; 7(1):. PubMed ID: 32213537
[TBL] [Abstract][Full Text] [Related]
24. The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia.
Currow DC; Skipworth RJ
Future Oncol; 2017 Aug; 13(20):1767-1783. PubMed ID: 28621564
[TBL] [Abstract][Full Text] [Related]
25. Factors associated with early discontinuation of anamorelin in patients with cancer-associated cachexia.
Tsukiyama I; Iwata T; Takeuchi T; Kato RI; Sakuma M; Tsukiyama S; Kato M; Ikeda Y; Ohashi W; Kubo A; Mori N
Support Care Cancer; 2023 Oct; 31(12):621. PubMed ID: 37815652
[TBL] [Abstract][Full Text] [Related]
26. Anamorelin for cancer anorexia-cachexia syndrome: a systematic review and meta-analysis.
Bai Y; Hu Y; Zhao Y; Yu X; Xu J; Hua Z; Zhao Z
Support Care Cancer; 2017 May; 25(5):1651-1659. PubMed ID: 28074289
[TBL] [Abstract][Full Text] [Related]
27. Effect of ghrelin and anamorelin (ONO-7643), a selective ghrelin receptor agonist, on tumor growth in a lung cancer mouse xenograft model.
Northrup R; Kuroda K; Duus EM; Barnes SR; Cheatham L; Wiley T; Pietra C
Support Care Cancer; 2013 Sep; 21(9):2409-15. PubMed ID: 23579947
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of anamorelin in patients with cancer cachexia: Post-hoc subgroup analyses of a placebo-controlled study.
Takayama K; Takiguchi T; Komura N; Naito T
Cancer Med; 2023 Feb; 12(3):2918-2928. PubMed ID: 36394148
[TBL] [Abstract][Full Text] [Related]
29. The effect of anamorelin (ONO-7643) on cachexia in cancer patients: Systematic review and meta-analysis of randomized controlled trials.
Rezaei S; de Oliveira LC; Ghanavati M; Shadnoush M; Akbari ME; Akbari A; Hadizadeh M; Ardehali SH; Wakabayashi H; Elhelali A; Rahmani J
J Oncol Pharm Pract; 2023 Oct; 29(7):1725-1735. PubMed ID: 37525932
[TBL] [Abstract][Full Text] [Related]
30. [The Treatment of Cancer Cachexia].
Tanaka S; Takayama K
Gan To Kagaku Ryoho; 2021 Aug; 48(8):987-991. PubMed ID: 34404062
[TBL] [Abstract][Full Text] [Related]
31. Plain language summary of a clinical study: anamorelin for treatment of Japanese people with non-small cell lung cancer and cachexia.
Takayama K
Future Oncol; 2024 Jun; ():1-11. PubMed ID: 38868904
[TBL] [Abstract][Full Text] [Related]
32. [The Second Web Questionnaire Survey on Cancer Cachexia Japanese Evidence for Patients Of Cancer Cachexia Ⅱ (J-EPOCC Ⅱ)-Disease Awareness and Issues Related to Cancer Cachexia Among Healthcare Professionals].
Kiguchi M; Kanemata S; Machii K; Doi I; Kinoshita F
Gan To Kagaku Ryoho; 2024 Mar; 51(3):275-281. PubMed ID: 38494808
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological management of cachexia in adult cancer patients: a systematic review of clinical trials.
Advani SM; Advani PG; VonVille HM; Jafri SH
BMC Cancer; 2018 Nov; 18(1):1174. PubMed ID: 30482179
[TBL] [Abstract][Full Text] [Related]
34. Plain language summary of a clinical study: anamorelin for treatment of Japanese people with gastrointestinal cancer and cachexia.
Takayama K; Furuse J; Muro K
Future Oncol; 2024 Jun; ():1-10. PubMed ID: 38864287
[TBL] [Abstract][Full Text] [Related]
35. Combination therapy with anamorelin and a myostatin inhibitor is advantageous for cancer cachexia in a mouse model.
Hanada K; Fukasawa K; Hinata H; Imai S; Takayama K; Hirai H; Ohfusa R; Hayashi Y; Itoh F
Cancer Sci; 2022 Oct; 113(10):3547-3557. PubMed ID: 35849084
[TBL] [Abstract][Full Text] [Related]
36. Adverse Metabolic Effects on Glucose in Patients Receiving Anamorelin Using a Japanese Claims Database.
Ohta H; Horii T; Yasu T
Oncology; 2023; 101(12):782-785. PubMed ID: 37579746
[TBL] [Abstract][Full Text] [Related]
37. Therapeutic potential of anamorelin, a novel, oral ghrelin mimetic, in patients with cancer-related cachexia: a multicenter, randomized, double-blind, crossover, pilot study.
Garcia JM; Friend J; Allen S
Support Care Cancer; 2013 Jan; 21(1):129-37. PubMed ID: 22699302
[TBL] [Abstract][Full Text] [Related]
38. [The Second Web Questionnaire Survey on Cancer Cachexia Japanese Evidence for Patients Of Cancer CachexiaⅡ (J-EPOCCⅡ)-Challenges in Early Detection and Early Intervention for Appetite Loss and Weight Loss During Cancer Treatment].
Kiguchi M; Kanemata S; Machii K; Doi I; Kinoshita F
Gan To Kagaku Ryoho; 2024 Feb; 51(2):159-165. PubMed ID: 38449402
[TBL] [Abstract][Full Text] [Related]
39. Prokinetics and ghrelin for the management of cancer cachexia syndrome.
Malik JS; Yennurajalingam S
Ann Palliat Med; 2019 Jan; 8(1):80-85. PubMed ID: 30525771
[TBL] [Abstract][Full Text] [Related]
40. Predictors of efficacy of anamorelin in patients with non‑small cell lung cancer and cachexia: A retrospective study.
Ishioka Y; Tanaka H; Makiguchi T; Fujishima S; Nunomura Y; Sakamoto H; Shiratori T; Taima K; Tasaka S
Oncol Lett; 2024 Jan; 27(1):22. PubMed ID: 38058465
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
